- Glenmark is concluding the final, national phase of its MAA process to enable launch of its innovative nasal spray, Ryaltris (olopatadine hydrochloride, 665mcg and mometasone furoate, 25mcg), in 17 countries in the EU
- Menarini will lead the commercialization in France, Italy, Spain, and the Balkan region under its collaboration with Glenmark signed in 2020. Glenmark has also partnered with Hikma and Bausch Health for the commercialization of Ryaltris in the US and Canada respectively
- Ryaltris is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients aged >12yrs.
Click here to read full press release/ article | Ref: PRNewswire | Image: Wikipedia